Tiaa, Fsb Regeneron Pharmaceuticals, Inc. Transaction History

Tiaa, Fsb

$27.6 Billion
Q2 2023

A detailed history of Tiaa, Fsb transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Tiaa, Fsb holds 2,613 shares of REGN stock, worth $2.72 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,613

Previous 2,832 7.73%

Holding current value

$2.72 Million

Previous $2.33 Million 19.3%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 31, 2023	SELL	$700.03 - $830.35 $153,306 - $181,846	-219 Reduced 7.73%	2,613 $1.88 Million
Q1 2023 Apr 19, 2023	BUY	$680.49 - $826.97 $31,983 - $38,867	47 Added 1.69%	2,832 $2.33 Million
Q4 2022 Jan 12, 2023	BUY	$705.89 - $766.39 $660,713 - $717,341	936 Added 50.62%	2,785 $2.01 Million
Q3 2022 Oct 11, 2022	SELL	$573.97 - $724.32 $8,609 - $10,864	-15 Reduced 0.8%	1,849 $1.27 Million
Q2 2022 Aug 09, 2022	BUY	$548.35 - $738.84 $1.02 Million - $1.38 Million	1,864 New	1,864 $1.1 Million
Q1 2019 Apr 15, 2019	SELL	$372.08 - $439.57 $3.86 Million - $4.56 Million	-10,374 Closed	0 $0
Q4 2018 Apr 15, 2019	BUY	$335.82 - $403.04 $3.48 Million - $4.18 Million	10,374 New	10,374 $3.88 Million
Q4 2018 Feb 22, 2019	SELL	$335.82 - $403.04 $3.8 Million - $4.56 Million	-11,307 Closed	0 $0
Q3 2018 Oct 18, 2018	SELL	$351.14 - $408.51 $96,914 - $112,748	-276 Reduced 2.38%	11,307 $4.57 Million
Q2 2018 Jul 20, 2018	SELL	$284.6 - $344.99 $2,846 - $3,449	-10 Reduced 0.09%	11,583 $4 Million
Q1 2018 Apr 18, 2018	BUY	$315.82 - $393.78 $3.66 Million - $4.57 Million	11,593 New	11,593 $3.99 Million

Others Institutions Holding REGN

# of Institutions

1,463

Shares Held

84.5M

Call Options Held

907K

Put Options Held

1.3M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $112B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tiaa, Fsb, based on Form 13F filings with the SEC.

News

Stay updated on Tiaa, Fsb with notifications on news.

Account